Synthesis and inhibitory effects of triarylpyrazoles on LPS-induced NO and PGE2 productions in RAW 264.7 macrophages

Park, Byung‐Jun; El‐Gamal, Mohammed I.; Lee, Woo-Suck; Shin, Ji‐Sun; Yoo, Kyung Ho; Lee, Kyung‐Tae; Oh, Chang‐Hyun

doi:10.1007/s00044-017-1923-9

Cited by 7 publications

(6 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Methodsmentioning

confidence: 99%

“…Cell culture and sample treatment were performed as reported in the literature [ 38 , 39 , 40 , 41 ]. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay for cell viability followed the procedure previously described in the literature [ 38 , 39 , 40 , 41 ]. Nitrite determination was carried as described in the literature [ 38 , 39 , 40 , 41 ], and the PGE 2 assay was carried as previously described [ 38 , 39 , 40 , 41 ].…”

Section: Methodsmentioning

confidence: 99%

“…Celecoxib is an anti-inflammatory drug that contains diarylpyrazole as a back bone and works through inhibition of the COX-2 enzyme [ 36 , 37 ]. Previously, we reported the synthesis of a series of triarylpyrazoles [ 38 , 39 , 40 , 41 ], from which compound I ( Figure 1 ) showed the highest activity for both nitric oxide and PGE 2 production inhibition [ 40 ]. In the current work and based on our previous work, we synthesized a new series of triarylpyrazole derivatives.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Synthesis of New Triarylpyrazole Derivatives Possessing Terminal Sulfonamide Moiety and Their Inhibitory Effects on PGE2 and Nitric Oxide Productions in Lipopolysaccharide-Induced RAW 264.7 Macrophages

et al. 2018

Self Cite

View full text Add to dashboard Cite

This article describes the design, synthesis, and in vitro anti-inflammatory screening of new triarylpyrazole derivatives. A total of 34 new compounds were synthesized containing a terminal arylsulfonamide moiety and a different linker between the sulfonamide and pyridine ring at position 4 of the pyrazole ring. All the target compounds were tested for both cytotoxicity and nitric oxide (NO) production inhibition in lipopolysaccharide (LPS)-induced RAW 264.7 macrophages. Compounds 1b, 1d, 1g, 2a, and 2c showed the highest NO inhibition percentages and the lowest cytotoxic effect. The most potent derivatives were tested for their ability to inhibit prostaglandin E2 (PGE2) in LPS-induced RAW 264.7 macrophages. The IC50 for nitric oxide inhibition, PGE2 inhibition, and cell viability were determined. In addition, 1b, 1d, 1g, 2a, and 2c were tested for their inhibitory effect on LPS-induced inducible nitric oxide synthase (iNOS) and Cyclooxygenase 2 (COX-2) protein expression as well as iNOS enzymatic activity.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Synthesis of New Triarylpyrazole Derivatives Possessing Terminal Sulfonamide Moiety and Their Inhibitory Effects on PGE2 and Nitric Oxide Productions in Lipopolysaccharide-Induced RAW 264.7 Macrophages

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…Several pyrazole derivatives exhibited higher selectivity in the inhibition of the ovine [16,26,32–34,44,46–50] or human [35–37,51–55] recombinant COX‐2. Like COX‐2, the inhibition of LOX is important for the development of nonulcerogenic and cardiotoxic drugs [56–58].…”

Section: Preclinical and Mechanistic Studies Of Pyrazoles Derivativesmentioning

confidence: 99%

“…The diaryl pyrazoles ( 10 ; 11 ) inhibited COX‐2 and 15‐LOX, while others ( 15 ; 16–19 ; 46 ; 82–84 ) inhibited COX‐2 and 5‐LOX [16,18,38,41,42] in an immunoassay. The pleural exudate ( 44 ) [46], cerebrospinal fluid ( 77 ) [44], blood samples ( 49 ; 63–66 ) [40,52], or cell culture of RAW 264.7 macrophages ( 56 ; 59 ) revealed that some compounds were able to reduce PGE 2 levels [51,59]. As reported for derivative 49 [52], the decrease of cytosolic and microsomal PGE 2 synthase concentration can also be measured to elucidate if compounds were able to block the prostaglandin production beyond the COX‐2 inhibition.…”

Section: Preclinical and Mechanistic Studies Of Pyrazoles Derivativesmentioning

confidence: 99%

Development of pyrazole derivatives in the management of inflammation

Turones

Martins

Moreira

et al. 2020

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

The therapeutic limitations and poor management of inflammatory conditions are anticipated to impact patients negatively over the coming decades. Following the synthesis of the first pyrazole—antipyrine in 1887, several other derivatives have been screened for anti‐inflammatory, analgesic, and antipyretic activities. Arguably, the pyrazole ring, as a major pharmacophore and central scaffold partly, defines the pharmacological profile of several derivatives. In this review, we explore the structural–activity relationship that accounts for the pharmacological profile of pyrazole derivatives and highlights future research perspectives capable of optimizing current advancement in the search for safe and efficacy anti‐inflammatory drugs. The flourishing research into the pyrazole derivatives as drug candidates has advanced our understanding of inflammation‐related diseases and treatment.

show abstract

Discovery of highly potent V600E-B-RAF kinase inhibitors: Molecular modeling study

Tarazi

El‐Gamal

2019

Bioorganic & Medicinal Chemistry

View full text Add to dashboard Cite

Synthesis and inhibitory effects of triarylpyrazoles on LPS-induced NO and PGE2 productions in RAW 264.7 macrophages

Cited by 7 publications

References 20 publications

Synthesis of New Triarylpyrazole Derivatives Possessing Terminal Sulfonamide Moiety and Their Inhibitory Effects on PGE2 and Nitric Oxide Productions in Lipopolysaccharide-Induced RAW 264.7 Macrophages

Synthesis of New Triarylpyrazole Derivatives Possessing Terminal Sulfonamide Moiety and Their Inhibitory Effects on PGE2 and Nitric Oxide Productions in Lipopolysaccharide-Induced RAW 264.7 Macrophages

Development of pyrazole derivatives in the management of inflammation

Discovery of highly potent V600E-B-RAF kinase inhibitors: Molecular modeling study

Contact Info

Product

Resources

About